CRBU, US1420381089

Caribou Biosciences stock draws a Moderate Buy consensus

Published on 10/05/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Five analysts set a Moderate Buy consensus and a USD 7.75 average target for Caribou Biosciences stock. Q2 EPS beat estimates, while revenue missed.

CRBU, US1420381089, Illustration mit AI erstellt.

Caribou Biosciences stock (ISIN US1420381089) was last at USD 1.22 on Nasdaq on October 2, 2026, leaving the share 65.54 percent below its 52-week high of USD 3.54. The latest analyst consensus gives the clinical-stage biotechnology company a Moderate Buy rating and an average 12-month target of USD 7.75, according to MarketBeat on September 19, 2026.

Five analysts set the tone

The consensus covers five analysts: three rate the stock Buy, one rates it Strong Buy and one rates it Sell. At USD 7.75, the average target lies 535.25 percent above the USD 1.22 Nasdaq price, a wide gap that reflects the high expectations attached to Caribou's clinical pipeline.

Bank of America maintained a Buy rating while cutting its price objective from USD 6.00 to USD 5.00 on August 14, 2026, according to MarketBeat. Wall Street Zen later cut its rating from Hold to Sell on September 19, 2026, creating a clear counterpoint to the broader consensus.

Q2 revenue missed expectations

Caribou reported second-quarter 2026 earnings on August 13, 2026. The company posted EPS of negative USD 0.24, better than the USD 0.32 consensus loss, while revenue reached USD 1.50 million against expectations of USD 2.28 million, MarketBeat reported.

The contrasting figures matter: the quarterly loss beat expectations by USD 0.08, but revenue fell USD 0.78 million short of the consensus. Caribou's investor materials describe a clinical-stage CRISPR genome-editing company developing off-the-shelf CAR-T therapies for hematologic malignancies, including programs targeting lymphoma and multiple myeloma.

Stock remains at the yearly floor

Trading data show a 52-week range of USD 1.22 to USD 3.54, with volume of 866,573 shares and a market capitalization of USD 121.0 million on October 2, 2026. The last price matched the lower end of that range, putting clinical progress and funding capacity at the center of the valuation debate.

Caribou's shares therefore combine a modest current valuation with a large analyst target spread. For investors, the key distinction is between the favorable EPS comparison in the latest quarter and the weaker revenue result.